The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of early tumor shrinkage on survival in WJOG4407G trial, a randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab in first-line treatment for metastatic colorectal cancer.
 
Michitaka Nagase
No Relationships to Disclose
 
Kentaro Yamazaki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Hiroshi Tamagawa
No Relationships to Disclose
 
Shinya Ueda
No Relationships to Disclose
 
Takao Tamura
No Relationships to Disclose
 
Kohei Murata
No Relationships to Disclose
 
Takashi Tsuda
No Relationships to Disclose
 
Eishi Baba
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - Chugai Pharma
 
Masahiro Tsuda
No Relationships to Disclose
 
Toshikazu Moriwaki
No Relationships to Disclose
 
Taito Esaki
No Relationships to Disclose
 
Yasushi Tsuji
No Relationships to Disclose
 
Kei Muro
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Merck Serono; Takeda; Yakult Honsha
 
Koichi Taira
No Relationships to Disclose
 
Tadamichi Denda
No Relationships to Disclose
 
Masahiko Ando
No Relationships to Disclose
 
Satoshi Morita
Honoraria - Chugai Pharma; Daiichi Sankyo
Consulting or Advisory Role - Chugai Pharma
 
Narikazu Boku
Honoraria - Daiichi Sankyo; Yakult Honsha
Research Funding - Yakult Honsha
 
Ichinosuke Hyodo
Honoraria - Chugai Pharma; Yakult Honsha